S261: SAFETY AND PRELIMINARY EFFICACY FINDINGS OF AUTO4, A TRBC1-TARGETTING CAR, IN RELAPSED/REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA

• K. Cwynarski,
• E. Tholouli,
• G. Iacoboni,
• T. Menne,
• D. Irvine,
• L. Wood,
• N. Balasubramaniam,
• J. Shang,
• M Zhang,
• K. Duffy,
• B. Huber,
• M. Vinson,
• W. Brugger,
• M. Pule

Affiliations

K. Cwynarski

1 Haematology, University College London, London

E. Tholouli

2 Manchester Royal Infirmary, Manchester, United Kingdom

G. Iacoboni

3 VHIO Vall d’Hebron Hospital, Barcelona, Spain

T. Menne

4 Freeman Hospital Newcastle, Newcastle

D. Irvine

5 University of Glasgow, Glasgow

L. Wood

6 Cancer Clinical Trials Unit, University College London Hospitals

N. Balasubramaniam

7 Cancer Clinial Trials Unit, University College London, London, United Kingdom

J. Shang

8 Autolus Therapeutics, Rockville, United States of America

M Zhang

8 Autolus Therapeutics, Rockville, United States of America

K. Duffy

9 Clinical Development, Autolus Therapeutics, London, United Kingdom

B. Huber

10 Autolus Therapeutics, Munich, Germany

M. Vinson

11 Autolus Therapeutics, London, United Kingdom

W. Brugger

9 Clinical Development, Autolus Therapeutics, London, United Kingdom

M. Pule

12 Research & Development, Autolus Therapeutics